Overview and Scope
Pediatric neuroblastoma treatment refers to a kind of treatment for cancer or a tumor that affects the nervous system in children. Neuroblastoma is typically treated with a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy.
Sizing and Forecast
The pediatric neuroblastoma treatment market size has grown rapidly in recent years. It will grow from $1.67 billion in 2023 to $1.84 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to advancements in treatment modalities, increased awareness and early diagnosis, research and development initiatives, collaborative efforts, improved survival rates.
The pediatric neuroblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to emerging therapies, personalized medicine, global health initiatives, expanded access to treatment, patient advocacy and support. Major trends in the forecast period include collaborative research initiatives, gene therapy breakthroughs, novel drug development, early diagnosis and screening, patient advocacy and support.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/pediatric-neuroblastoma-treatment-global-market-report
Segmentation & Regional Insights
The pediatric neuroblastoma treatment market covered in this report is segmented –
1) By Treatment Type: Immunotherapy, Chemotherapy, Radiation Therapy, Other Treatment Types
2) By Risk Group: Low Risk, Intermediate Risk, High Risk
3) By End User: Hospitals, Specialty Clinics, Other End Users
North America was the largest region in the pediatric neuroblastoma treatment market in 2023. The regions covered in the pediatric neuroblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9924&type=smp
Major Driver Impacting Market Growth
The rising number of new cases of pediatric neuroblastoma is expected to propel the growth of the pediatric neuroblastoma treatment market going forward. The rising prevalence of neuroblastoma is increasing the demand for pediatric neuroblastoma treatment alternatives. As a result, pharmaceutical corporations and other stakeholders have boosted their investment in research and development, promoting innovation in the industry. Furthermore, the availability of new diagnostic technology and screening procedures has resulted in earlier neuroblastoma discovery, allowing for earlier treatments and better outcomes. For instance, in March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), a US-based organization for oncology professionals and physicians, neuroblastoma affects approximately 700 to 800 youngsters in the United States each year. In the United States, neuroblastoma accounts for 6% of all childhood malignancies. Neuroblastoma affects around 90% of children under the age of five. Therefore, the rising number of new cases of pediatric neuroblastoma is driving the growth of the pediatric neuroblastoma treatment market.
Key Industry Players
Major companies operating in the pediatric neuroblastoma treatment market are adopting a strategic partnership approach aiming to produce novel drug for high-risk neuroblastoma. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based biopharmaceutical company, announced a license agreement with the St. Jude Children’s Research Hospital for Hu14.18, a humanized antibody that the institution is developing for the medical management of newly identified high-risk neuroblastoma. Hu14.18 is a humanised anti-GD2 mAb. A unique Phase II study adding Hu14.18 to both induction and post-consolidation treatment exhibited excellent patient outcomes with an OS of 86.0% and an EFS of 73.7%4. The licensing deal provides Renaissance Pharma with exclusive development, production, and commercialization rights in the United States, Canada, Europe, China, Japan, and Turkey. The St. Jude Children’s Research Hospital is a US-based research hospital.
The pediatric neuroblastoma treatment market report table of contents includes:
1. Executive Summary
2. Pediatric Neuroblastoma Treatment Market Characteristics
3. Pediatric Neuroblastoma Treatment Market Trends And Strategies
4. Pediatric Neuroblastoma Treatment Market – Macro Economic Scenario
5. Global Pediatric Neuroblastoma Treatment Market Size and Growth
…..
31. Global Pediatric Neuroblastoma Treatment Market Competitive Benchmarking
32. Global Pediatric Neuroblastoma Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Pediatric Neuroblastoma Treatment Market
34. Pediatric Neuroblastoma Treatment Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
